Active Pharmaceutical Ingredients (APIs)

  • Nilotinib HCI Dihydrate*

    • API Product   :   

      Nilotinib HCI Dihydrate*

    • CEP   :   

      -

    • WCC   :   

      ?

    • Therapeutic Use    :   

      Tyrosine Kinase Inhibitor(TKI)

    • Originator   :   

      Inhibikase Therapeutics

    • CAS No.    :   

      641571-10-0

    • Trade Name.   :   

      Tasigna

    • Molecular Weight   :   

      529.5245 g/mol

    • Molecular Formula   :   

      C28H22F3N7O

    Application

    Nilotinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old.

    General Description

    Nilotinib (AMN107, trade name Tasigna[2]), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.[3] Structurally related to imatinib,[4] it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance.[5][6][7] Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor[5][6] that is 10–30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.[4][6][7][8] Nilotinib was developed by Novartis and is sold under the trade name Tasigna.